Objective:

To evaluate the comparative effects of tirzepatide and semaglutide on weight, glycemic control, cardiovascular outcomes, and safety profiles in adults with obesity or T2DM, highlighting the clinical relevance of these comparisons.

Key Findings:

• Tirzepatide achieved greater reductions in body weight and HbA1c compared to semaglutide, indicating its potential as a first-line therapy.
• Semaglutide has more established evidence for cardiovascular risk reduction, making it a strong option for patients with cardiovascular concerns.
• Tirzepatide demonstrated cardiovascular non-inferiority compared to dulaglutide, suggesting it is a safe alternative.

Interpretation:

Tirzepatide shows superior metabolic efficacy, while semaglutide has stronger cardiovascular benefit evidence, indicating the need for tailored treatment strategies based on patient profiles.

Limitations:

• No original quantitative meta-analysis or formal risk-of-bias assessments were conducted, which may limit the robustness of the findings.
• Comparative cardiovascular outcomes rely on contextual data rather than direct head-to-head trials, which could introduce biases.

Conclusion:

Treatment selection should be individualized based on clinical priorities and patient characteristics, with an emphasis on the need for further research to solidify these findings.